What neuromodulators “BOTOX” are on the market?

Cosmetic Neuromodulators:

1. Botox (Botulinum Toxin Type A) – Allergan (now AbbVie):
   • Use: Primarily for reducing the appearance of facial lines and wrinkles.
   • FDA Approval: For glabellar lines, crow’s feet, and forehead lines.
2. Dysport (Botulinum Toxin Type A) – Galderma:
   • Use: Similar to Botox, for cosmetic wrinkle reduction.
   • FDA Approval: Also for glabellar lines, with some noting it might spread more diffusely than Botox.
3. Xeomin (IncobotulinumtoxinA) – Merz Pharmaceuticals:
   • Use: Cosmetic treatment of wrinkles and medical treatment for conditions like cervical dystonia.
   • Unique Feature: Free of complexing proteins, potentially reducing the risk of antibody formation over time.
4. Jeuveau (PrabotulinumtoxinA-xvfs) – Evolus:
   • Use: Focused on cosmetic treatment for glabellar lines.
   • Market Position: Marketed as a “newtox” for a younger demographic.
5. Daxxify (DaxibotulinumtoxinA-lanm) – Revance Therapeutics:
   • Use: Aimed at both cosmetic and therapeutic markets, specifically for moderate-to-severe glabellar lines.
   • Unique Feature: Formulated with a peptide technology, offering potentially longer-lasting effects (up to 6 months or more for some patients) compared to other neuromodulators.
   • FDA Approval: Approved for glabellar lines with ongoing research for additional indications like cervical dystonia.

Therapeutic Neuromodulators:

• Botox, Dysport, and Xeomin: Apart from cosmetic uses, these are approved for several medical conditions:
  • Chronic migraines
  • Cervical dystonia
  • Overactive bladder
  • Muscle spasticity
  • Hyperhidrosis (excessive sweating)
• Daxxify:
  • Use: Beyond its cosmetic use, it’s approved for treating cervical dystonia, which positions it as both a cosmetic and therapeutic neuromodulator.
  • FDA Approval: Received FDA approval for cervical dystonia, marking its entry into the therapeutic neuromodulator market.

6. Myobloc (RimabotulinumtoxinB) – Solstice Neurosciences (now part of US WorldMeds):
   • Use: Primarily for cervical dystonia, but also used off-label for other conditions.
   • Difference: Type B toxin, with different onset and duration compared to Type A toxins.

Emerging and Less Common Neuromodulators:

• Letybo (Botulinum Toxin Type A) – Hugel Inc.:
  • Use: Similar aesthetic applications, primarily marketed in Asia but expanding globally.
  • Status: Not yet widely available in the U.S. but approved in several countries.

Notes:

• Mechanism: All these neuromodulators work by blocking the release of acetylcholine, which prevents muscle contractions, thereby reducing wrinkles or treating muscle spasms.
• Differences: While all are botulinum toxins, they can differ in formulation, diffusion properties, onset time, duration of effect, and how they interact with the body due to different manufacturing processes or additives. Daxxify’s unique peptide-based formulation is a notable distinction.
• Market Trends: The neuromodulation market continues to grow with innovations focusing on longer-lasting effects, reduced side effects, and broader therapeutic applications.
• Safety and Efficacy: Each product has its own profile, but they are generally considered safe when administered by professionals for approved indications. However, off-label uses and individual responses can vary.

This overview now includes Daxxify, reflecting its dual role in both aesthetic and therapeutic applications, and its potential to change the landscape of neuromodulator treatments with its longer duration and peptide technology.

Learn more about neuromodulators at